StockData

Capricor Therapeutics vs Keros Therapeutics

CAPR and KROS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CAPR and KROS compare

Capricor Therapeutics is the larger company, worth 2.4 times as much as Keros Therapeutics ($483M against $199M).

Keros Therapeutics scores higher on the StockData Score (7 against 6 for Capricor Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCAPRKROS
Size and price
Market cap$483M$199M
Share price$8.30$10.03
Change, 1 year43.8%−42.0%
Change, 5 years143%−82.1%
Beta (5Y)0.432.22
Employees23178
StockData Score
Total score67 (better)
Valuation score11
Growth score00
Performance score01 (better)
Health score55
Dividend score00
Valuation
P/S–13.7×
P/B2.0×0.8× (better)
FCF yield−23.8% (better)−24.4%
Growth
Revenue growth (TTM)–−93.7%
Net income growth (TTM)–−543%
EPS growth (TTM)–−1287%
Profitability
Operating margin–−698%
Net margin–−572%
FCF margin–−334%
Return on equity−73.7%−17.2% (better)
Return on invested capital–−755%
Financial health
Debt / equity0.000.00
Current ratio7.3521.96 (better)
Altman Z-score0.392.07 (better)
Piotroski F-score36 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions67.6%101%
Held by insiders1.6%53.3%
Insider net buying, 12 months−$8.4M−$447K (better)
Short interest, % of float32.8%11.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.